NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov’t. agencies only; Proprietary Info.; Aug 99. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.

AUTHORITY
Award Number DAMD17-97-1-7268

TITLE: Apoptosis and Tumor Invasion in Breast Cancer

PRINCIPAL INVESTIGATOR: Martin Tenniswood, Ph.D.

CONTRACTING ORGANIZATION: The University of Notre Dame
Notre Dame, Indiana 46556-5612

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Aug 99). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-97-1-7268
Organization: The University of Notre Dame

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure, or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release, or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure, or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

[Signature]  9/16/02

__________________________  ___________________________
**REPORT DOCUMENTATION PAGE**

**Agency Use Only (Leave Blank)**

**Title and Subtitle**
Apoptosis and Tumor Invasion in Breast Cancer

**Funding Numbers**
DAMD17-97-1-7268

**Performing Organization Name(s) and Address(es)**
The University of Notre Dame
Notre Dame, Indiana 46556-5612

**Sponsoring / Monitoring Agency Name(s) and Address(es)**
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**Abstract (Maximum 200 Words)**

**Subject Terms**

**Security Classification of Report**
Unclassified

**Security Classification of This Page**
Unclassified

**Security Classification of Abstract**
Unclassified

**Limitation of Abstract**
Limited

NSN 7540-01-280-5500

---

**Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.**
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
Table of Contents

Cover
SF 298
Foreword
Table of Contents
Body 1-9
Annual Report for Grant Number DAMD 17-97-7298
Covering Period September 1, 1998 to August 31, 1999

Title: Apoptosis and Tumor Invasion in Breast Cancer

Revised Statement of Work

Specific Aim 1: Characterize the ability of anti-estrogens to induce apoptosis and an invasive phenotype in a sub-population of cells in vitro

Task 1 (months 1-4): Develop time and dose dependence of acquisition of invasive phenotype of parental MCF-7 cell line [status: completed]

Task 2 (months 12-18): Characterize changes in gene expression and DNA fragmentation associated with the acquisition of the invasive phenotype in parental MCF-7 cells. [status: nearly completed]. RNA and protein have been extracted from the parental cell line, and the level of several transcripts, including clusterin, cathepsin B and uPA have been assessed by RT-PCR. The protein levels have been assessed by Western analysis. DNA fragmentation remains to be assessed by gel electrophoresis and by TUNEL staining. Immunofluorescence remains to be completed. Estimated revised time frame: These experiments should be completed between months 20-30.

Task 3 (months 2-8): Develop clonal MCF-7\textsuperscript{ae}\textsubscript{inv} sublines of invasive cells. [status: completed]. We have isolated and clonally selected a number of MCF-7\textsuperscript{ae}\textsubscript{inv} sublines, and have demonstrated that some, but not all, of the cell lines have retained sensitivity to ICI 182,780.

Task 4 (months 8-12): Characterize changes in gene expression associated with stable acquisition of invasive phenotype in MCF-7\textsuperscript{ae}\textsubscript{inv} sublines. [status: partially complete]. We have isolated RNA and protein from several of the MCF-7\textsuperscript{ae}\textsubscript{inv} sublines and level, and we are now performing RT-PCR and Western analyses to establish the changes in the levels of the relevant transcripts and proteins in the invasive sublines. Estimated revised time frame: These experiments should be completed between months 20-30.

Task 5 (months 12-15): Characterize the sensitivity of MCF-7\textsuperscript{ae}\textsubscript{inv} to TNF\alpha and anti-estrogens (tamoxifen, 4-hydroxytamoxifen and ICI 182,780) [status: partially complete]. We are comparing the sensitivity of these cell lines to other anti-estrogens (tamoxifen and 4-hydroxytamoxifen) to identify cell lines that have retained their sensitivity to anti-estrogens and others that have developed resistance to the drugs. There appear to be several different sensitivity profiles, and we are still cataloguing these profiles to determine whether there is an underlying biological explanation for
these differences that can be linked to estrogen receptor levels or the ability of the cells to initiate cell death. **Estimated revised time frame:** These experiments should be completed between months 30-36.

**Specific Aim 2:** Compare the sensitivity of the MCF-7<sup>ae<sub>inv</sub></sup> sublines to other agents that induce apoptosis and determine if multiple agents can act synergistically to induce apoptosis.

1. **Task 1 (months 12-18):** Characterize the effects of EB1089 and onapristone on apoptosis and invasion in parental MCF-7 cells compared to MCF-7<sup>ae<sub>inv</sub></sup> sublines. **[Status: recently initiated]**. Very preliminary results, that need to be repeated have suggested that most MCF-7<sup>ae<sub>inv</sub></sup> sublines are still sensitive to the synthetic vitamin D analog EB1089. **Estimated revised time frame:** These experiments should be completed between months 24-30.

2. **Task 2 (months 12-18):** Characterize the effects of simultaneous administration of anti-estrogen and EB1089 or onapristone on apoptosis and acquisition of the invasive phenotype on parental MCF-7 cells. Characterize the changes in gene expression and DNA fragmentation. **[Status: not yet initiated]**. **Estimated revised time frame:** These experiments should be completed between months 30-36.

3. **Task 3 (months 15-24):** Develop clonal MCF-7<sup>ona<sub>inv</sub></sup> and MCF-7<sup>D<sub>3</sub>inv</sup> and compare their sensitivity to anti-estrogens and TNFα. **Estimated revised time frame:** These experiments should be completed between months 33-36.

4. **Task 4 (months 12-24):** Determine degree of cross sensitivity for each invasive cell type and characterize changes in gene expression. **Estimated revised time frame:** These experiments should be completed between months 33-36. **Task 4 cannot be initiated before task 3 has been completed.**

As we have pointed out previously, prior to the initiation of the research we were asked to describe how we would pursue this work *in vivo* as part of a follow up study. At that time we added specific aim 3 to the research program, with the understanding that this specific aim was outside the scope of the two year funding period.

**Specific Aim 3:** To determine whether treatment with anti-estrogens or other apoptosis inducing reagents (such as vitamin D analogs) alters the rate and/or sites of metastasis and whether invasive cells generated by treatment with one reagent are sensitive to treatment with other reagents that induce cell death *in vivo*. To perform these experiments we modified our experimental timetable to include an additional preliminary task: the development of estrogen sensitive clonal cell lines expressing enhanced Green Fluorescence Protein (GFP). We have therefore developed a number of MCF-7<sup>GFP</sup> sublines, and have compared the effects of anti-estrogens on these breast cancer cell lines to ensure
that the transfected cells retained their normal estrogen dependence and their responsiveness to anti-estrogens. [status completed]. These cell lines are currently being analyzed in parallel with the parental MCF-7 cells, we are isolating MCF-7GFP that are also invasive, and we are characterizing the sensitivity of these fluorescent sublines to anti-estrogens and TNFα. We have identified several MCF-7GFP sublines that has the same characteristics as the parental line so that we can perform the in vitro studies proposed in specific aim 3, using thoroughly tested, appropriate cell lines in these latter experiments. We are currently testing these cell lines in parallel with the parentla MCF-7 cells and are trying to isolated MCF-7GFPInv cell lines comparable to those we have derived from the parental line [status: partially complete]. Estimated revised time frame: These experiments should be completed between months 36-40. This timeline extends beyond the 3 year funding period, but as we have pointed out in our initial description of specific aim 3 and the progress report, we understand that funding for the in vivo studies which would be initiated after month 36, has not been secured, and is not guaranteed.

Note these time estimates are made on the basis that the grant period is now 36 months, and that the clock did not stop during the hiatus caused by our move from the Adirondack Biomedical Research Institute.

Effect of Move on the Project:

The transfer of our laboratory from the Adirondack Biomedical Research Institute (formerly the W. Alton Jones Cell Science Center) in Lake Placid to the Department of Biological Sciences at the University of Notre Dame, and the delay in transferring the grant to the new institution resulted in an 8 month hiatus. This coupled with the no-cost extension from the university, now puts us on target to complete the research in June, 2000. This effectively puts the project, which was originally planned as a two year program, in synchrony with the three year grants awarded by the DAMD in 1997. The data presented in this report will be presented at the Era of Hope Meeting in Atlanta Georgia in June 2000.

Other than the downtime, we have not experienced any adverse effects on the project resulting from the move. We have re-established each of the cell lines in culture since we moved and have demonstrated that the parental MCF-7 and the MCF-7GFP cell lines have not been affected by the move. The facilities available in our new laboratories, which were constructed to our specifications, are considerably superior to the facilities we left in Lake Placid. A number of new instruments including superior microscopes and electronic image documentation and analysis for microscopy and gel electrophoresis (Western and RT-PCR) will significantly improve our throughput, making it possible to catch up for lost time.
In the original application there were two specific aims:

**Specific Aim 1.** To characterize the ability of anti-estrogens to induce apoptosis and an invasive phenotype in a sub-population of cells in vitro.

**Specific Aim 2.** To compare the sensitivity of MCF-7\textsuperscript{aenv} sublines to other agents that induce apoptosis and determine if multiple agents can act synergistically to induce apoptosis.

**Progress since Re-initiation of the Grant**

We have compared the effects of several anti-estrogens to TNF\(\alpha\) on MCF-7\textsuperscript{wt} cells. We have established that the anti-estrogens induce cell cycle arrest and apoptosis of MCF-7\textsuperscript{wt} cells in a dose manner (Fig. 1). These data demonstrate that the MCF-7\textsuperscript{wt} display differential sensitivities to the individual anti-estrogens. Of the anti-estrogens tamoxifen and 4-hydroxytamoxifen appear to be considerably more potent (with an LD\textsubscript{50} of approximately 0.1 \(\mu\)M), than the pure anti-estrogen, ZM 182, 780 (LD\textsubscript{50} of 2 \(\mu\)M). Time course analysis of the effects of selected doses of each anti-estrogen demonstrates that 1 \(\mu\)M tamoxifen induces a clear reduction in cell number, while 1\(\mu\)M 4-hydroxytamoxifen and 10\(\mu\)M ZM 182,780 block the increase in cell numbers seen in the control, untreated cells. Flow cytometry studies have shown that the effects of all three anti-estrogens is due to a combination of cell cycle arrest and apoptosis (data not shown). Regardless of the dose and time of treatment it is important to recognize that a significant number of cells survive the anti-estrogen treatments.

We have now demonstrated that...
a sub population of MCF-7WT that survive anti-estrogen therapy acquire an invasive phenotype after treatment. In preliminary experiments we have established the appropriate parameters for measuring the the ability of the MCF-7WT and MCF-7GFP cells to invade through Matrigel in a modified Boyden chamber assay, by monitoring cell number (measured by crystal violet staining) or intrinsic GFP fluorescence as they pass through the Matrigel and membrane of the chamber before and after treatment with anti-estrogens. As shown in Figure 3, MCF-7WT cells do not invade through 8μ invasion filters coated with a thick layer of Matrigel in the absence of the anti-estrogens. However after treatment with tamoxifen or 4OH-tamoxifen, a sub population of the surviving cells acquire an invasive phenotype. Treatment of the MCF-7WT cells with TNFα or ZM 182,780 (which also induce cell death), does not induce an invasive phenotype in the surviving cells. It is clear that treatment with tamoxifen or 4-OH tamoxifen increases the invasive potential of the MCF-7 cells to a level that is equal to or exceeds that of the SUM159T cells, a breast cancer cell line that we have shown is invasive in vitro and metastatic in vivo. As Figure 4 demonstrates the acquisition of the invasive phenotype is enhanced by the chemotatic attractants in fibroblast-conditioned medium (presumably growth factors such as basic FGF and FGF-9), but the invasive cells do not require the presence of the conditioned medium to manifest the phenotype.

These studies confirm that a small sub-population of cells that survive anti-estrogen therapy become invasive. Preliminary data, based on RT-PCR, demonstrate that anti-estrogen treatment of these sublines induces the synthesis of several extracellular proteases (notably cathepsin B ) while down-regulating the synthesis of at least one inhibitor of the matrix metalloproteases (TIMP-1). While these data clearly offer support
to our hypothesis, they need to be repeated under rigorous experimental conditions to confirm this observation and to determine which other extracellular proteases (and acid hydrolases) are induced after treatment with anti-estrogens. We will also determine which inhibitors of matrix metalloproteases and cathepsins are simultaneously down regulated.

Figure 4
Effect of fibroblast-conditioned medium in the acquisition of the invasive phenotype. MCF-7wt cells were grown, and treated with the indicated anti-estrogens as described in figure 3. Equal numbers of cells were plated on 8μ membranes coated with Matrigel. The lower chamber contained either α-MEM (blue) or fibroblast conditioned medium (purple). Cell numbers in the lower chambers were determined 48 h later by crystal violet. The data were compared to the level of invasion using a known metastatic cell line (SUM 159T cells).

Prior to the initiation of the research we were asked to describe how we would pursue this work in vivo as part of a follow up study. At that time we added specific aim 3 to the research program, with the understanding that this specific aim was outside the scope of the two funding period.

Specific Aim 3: To determine whether treatment with anti-estrogens or other apoptosis inducing reagents (such as vitamin D analogs) alters the rate and/or sites of metastasis and whether invasive cells generated by treatment with one reagent are sensitive to treatment with other reagents that induce cell death in vivo.

While specific aim 3 was clearly not part of the original application, our proposal to use MCF-7 cells transfected with GFP (green fluorescent protein) to monitor invasive cells both in vitro and in vivo suggested to us that we would be well advised to create these MCF-7GFP sublines before proceeding to examine the effects of anti-estrogens on these breast cancer cell lines to ensure that the transfected cells retained their normal estrogen dependence and their responsiveness to anti-estrogens.
We have therefore modified our original experimental timetable to include an additional preliminary task: the development of estrogen sensitive clonal cell lines expressing enhanced Green Fluorescence Protein (GFP). These cell lines have been developed by transfecting estrogen dependent MCF-7 cell with pEGFP-c1, a plasmid containing the enhanced green fluorescent protein under the control of the constitutive CMV promoter, and an ampicillin selectable marker. These cells were cultured for 7 days, and then sorted on a Becton-Dickinson fluorescence activated cell sorter into 96-well culture plates using the autosort facility of the machine. The cells in individual wells were clonally expanded to produce a series of high, medium and low GFP-expressing sublines by growth in G418. A total of 20 sublines have been stabilized, characterized and frozen in liquid nitrogen for further use. Phase contrast and fluorescence photomicrographs of one of these sublines is shown in Figure 5, demonstrating that virtually all of the cells within the selected subline express GFP at approximately the same level.

In our initial experiments we have established that transfection of the MCF-7 cells with the GFP construct has not significantly affected the cell cycle kinetics (Fig. 6). Both MCF-7WT and MCF-7GFP have essentially the same proportion in each phase of the cell cycle, suggesting that the GFP transfection has not altered the cell cycle kinetics. We have also compared the sensitivity of these sublines to TNF-α with that of the
parental MCF-7 wild type cells (MCF-7WT). Without exception, the MCF-7GFP, retain their sensitivity to TNF-α and demonstrate a very similar dose response to the drug as the parental wild type MCF-7 cells, suggesting that the expression of GFP in these cells does not influence the ability of the transfected cells to undergo apoptosis after the appropriate stimulation (Fig. 8).

Most, but not all of the transfected sublines have also retained their sensitivity to anti-estrogens and induce cell death (as monitored by DNA fragmentation (TUNEL positivity) and cell viability as monitored by crystal violet or flow cytometry. The relative sensitivity of the subline shown in Fig 1 and 2, to ZM182,780, tamoxifen and 4-hydroxytamoxifen is shown in Fig 3. The results demonstrate that this particular subline retains its sensitivity to all three anti-estrogens, and like the parental MCF-7 cell line appears to be sensitive to the pure anti-estrogen ZM 182,780 only at higher concentrations (> 1 μM), even though the overall rate of cell death appears to be of the same order of magnitude (approximately 40% of the cells appear to survive anti-estrogen therapy for 72h). Most of the sublines display similar sensitivities to the individual anti-estrogens although we have not yet
determined whether the (minor) variations we see are reproducible or biologically significant.

Importantly, both tamoxifen and 4OH tamoxifen induce an invasive phenotype in the MCF-7 \textsuperscript{GFP} as they do with the MCF-7 \textsuperscript{WT} cells (Fig. 8), suggesting that these cells are suitable for the \textit{in vivo} studies outlined in specific aim 3.

\textbf{In summary, the experiments required to complete Specific Aims 1 and 2 will be completed within the next 6-8 months, and the initial experiments required for the initiation and completion of specific aim 3 have been completed. It is our intention to apply for a new grant from DAMD for the studies outlined in specific aim 3 in the next competition.}
MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for grants. Request the limited distribution statements for the Accession Document Numbers listed at enclosure be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

[Signature]

PHYLLIS M. RINEHART
Deputy Chief of Staff for Information Management

Enclosure